IRGD
Early humanTumour penetrating cyclic RGD derived peptide
Research material. Not for human or animal consumption.
Research overview
iRGD is a cyclic nine-amino-acid peptide, CRGDKGPDC, discovered by Erkki Ruoslahti's laboratory in 2009. It works in three steps: its RGD motif binds αv integrins on tumour blood vessels, it is then cut by a protease to expose a C-terminal R/KXXR 'CendR' motif, and that motif binds neuropilin-1, opening a transport route deeper into the tumour. Co-administered drugs and nanoparticles also penetrate more. Under the names CEND-1, LSTA1 and certepetide, it has been tested in early trials in pancreatic cancer.
Limited, exploratory, early phase or small human studies have been identified.
Questions about IRGD
PRODUCT QUESTIONSWhat is IRGD?
IRGD is a cyclic nine residue peptide, cysteine, arginine, glycine, aspartic acid, lysine, glycine, proline, aspartic acid, cysteine, closed by a disulfide bond. Its development names include CEND 1, LSTA1 and certepetide.
What research has been published on IRGD?
Research spans cell and tumour spheroid uptake studies, conjugation to nanoparticles and imaging agents, and mouse cancer models showing deeper drug penetration. Early human studies combined the related development compound with chemotherapy in metastatic pancreatic cancer.
What batch documentation should accompany IRGD?
IRGD: Ask for the COA and analytical reports for the batch being quoted. Ask for mass spectrometry confirming the cyclic disulfide form, HPLC purity with the linear peptide reported, and, for conjugates, the dye or label loading.
How should IRGD storage conditions be assessed?
Store IRGD lyophilised at −20°C, dry and away from light. Avoid reducing agents, which open the ring, and keep solutions slightly acidic and cold.
Request a quotation
Enquire about IRGD and the documentation for the available batch.
Request a quotation